Show simple item record

dc.contributor.authorBerro, Mariano.
dc.contributor.authorPalau Nagore, M. V.
dc.contributor.authorRivas, M.
dc.contributor.authorLongo, Pablo.
dc.contributor.authorFoncuberta, Cecilia.
dc.contributor.authorVitriú, Adriana.
dc.contributor.authorRemaggi, G.
dc.contributor.authoret al.
dc.date.accessioned2020-02-17T18:43:42Z
dc.date.available2020-02-17T18:43:42Z
dc.date.issued2017-05-01
dc.identifier.citationBone Marrow Transplant. 2017 May;52(5):739-744.en_US
dc.identifier.issn0268-3369
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/804
dc.description.abstractHematopoietic stem cell transplantation (HSCT) with sibling donors (s.d.) is a life-saving intervention for patients with hematological malignancies. Numerous genetic factors have a role in transplant outcome. Several functional polymorphisms have been identified in TGF-β1 gene, such as single-nucleotide polymorphism (SNP) at +29C>T within exon 1. Two hundred and forty five patient/donor pairs who underwent a s.d. HSCT in our centers were genotyped for this SNP. In the myeloablative cohort, +29CC donors were associated with an increase in severe chronic GvHD (32% vs 16%, hazard ratio (HR) 9.0, P=0.02). Regarding survival outcomes, +29CC patients developed higher non relapse mortality (NRM) (1-5 years CC 28-32% vs TC/TT 7-10%; HR 5.1, P=0.01). Recipients of +29TT donors experienced a higher relapse rate (1-5 years TT 37-51% vs TC 19-25% vs CC 13%-19%; HR 2.4, P=0.01) with a decreased overall survival (OS) (1-5 years TT 69-50% vs TC/CC 77-69%; HR 1.9, P=0.05). Similar to previous myeloablative unrelated donors HSCT results, we confirmed that +29CC patients had higher NRM. In addition we found that +29TT donors might be associated with a higher relapse rate and lower OS. These results should be confirmed in larger series. Identification of these SNPs will allow personalizing transplant conditioning and immunosuppressant regimens, as well as assisting in the choice of the most appropriate donor.en_US
dc.language.isoenen_US
dc.publisherSpringer Nature [academic journals on nature.com]en_US
dc.subjectRecurrenceen_US
dc.subjectGraft vs Host Disease/geneticsen_US
dc.subjectHematologic Neoplasms/therapyen_US
dc.subjectTransforming Growth Factor beta1/genetics*en_US
dc.titleTransforming growth factor-β1 functional polymorphisms in myeloablative sibling hematopoietic stem cell transplantationen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record